Table 3 Cancer risk estimates for gene-gene combinations of A) rs12945597 (TOP3A) and rs2532105 (BLM) and B) rs1563634 (TOP3A) and rs2532105 (BLM) in different cancer forms.^a

AML/MDS

GG+CC

1.0

-

GG+T-

1.4

0.61–3.0

A-+CC

1.6

0.89–2.8

A-+T-

2.4

1.1–5.4

Malignant melanoma

GG+CC

1.0

-

A-+CC

1.7

0.98–3.0

GG+T-

2.5

1.2–5.2

A-+T-

2.4

1.1–5.4

Bladder cancer

GG+CC

1.0

-

A-+CC

1.4

0.68–2.9

GG+T-

2.1

0.74–6.1

A-+T-

3.0

1.1–7.7

Breast cancer

GG+CC

1.0

-

A-+CC

1.5

0.92–2.6

GG+T-

2.0

1.0–4.1

A-+T-

3.0

1.4–6.4

IIIB. rs1563634^b+rs2532105

Genotype

OR

95% CI

AML/MDS

AA+CC

1.0

-

AA+T-

0.48

0.087–2.7

G-+CC

1.1

0.39–3.1

G-+T-

1.9

0.62–5.8

Malignant melanoma

AA+CC

1.0

-

AA+T-

0.48

0.089–2.6

G-+CC

1.1

0.41–3.1

G-+T-

2.5

0.84–7.4

Bladder cancer

AA+CC

1.0

-

AA+T-

1.7

0.12–23

G-+CC

3.0

0.64–14

G-+T-

6.5

1.3–33

Breast cancer

AA+CC

1.0

-

G-+CC

2.8

1.1–7.2

AA+T-

12

2.1–70

G-+T-

4.6

1.7–13